All you need in Forex
story by: Amandeep Sonewane
20-24 March Weekly Stock Market Outlook: Hidden bullish signals on this stock
20/03/2017
20-24 March Weekly Stock Market Outlook: Hidden bullish signals on this stock

MMy 20-24 March Weekly Stock Market Outlook is bullish as the Dow is making an another turn towards 21,000 levels. Here are the 3 Stocks to focus this week.

20 March, AtoZForex – The Dow Jones Industrial Average has reached 20,923.13 points today after the previous close of 20,914.62 points. Dow Jones has outperformed due to Trump stock market rally and surged around 20 percent. The NASDAQ and S&P 500 also has outperformed this week and the chances are even higher for the stocks to hit new targets.

20-march-us-market

 

20-24 March Weekly Stock Market Outlook

Here are the 3 stocks that the traders should buy quickly to earn the profit by the end of this week.

Pepsico, Inc. (NYSE: PEP)

Pepsi pays a quarterly dividend totaling $3.01 annually, which currently yields 2.71 percent. Pepsi has a market capitalization of $158.98 billion, and last reported a cash position of $16.12 billion, $36.94 billion in debt, and a debt-to-equity ratio of 329.90 percent. My target for this stock is 114-115 this week. The SMA 100 lines are below the SMA 50 line which is good for the stock. The Relative strength index for this stock is 63.95 which signify buying signal. But the investor should use a stop loss of 109 for this stock.

20-march-pepsico

General Electric Company (NYSE: GE)

pays quarterly dividends totaling $0.96 annually, yielding 3.23 percent. GE has a market capitalization of $260.22 billion, last reported holding a cash position of $10.52 billion, $136.21 billion in debt, and a debt-to-equity ratio of 169.17 percent. My weekly target for this stock is 31-32.5 points for this week. Moreover, the investors should wait for the long term plan for this stock and should not go for investment. But the stock is worth buying for weekly basis and gives you a moderate profit.

20-march-ge

Nektar Therapeutics (NASDAQ: NKTR)

Nektar Therapeutics (NASDAQ: NKTR) surged more than 32 percent today after an announced on Monday morning that its Phase 3 efficacy study of NKTR-181 met the primary efficacy endpoint, demonstrating significantly improved chronic back pain relief. The stock has gapped open sharply higher this morning and is now up 3.56 at $19.06 on above average volume. The stock has surged to nearly a 6-month high. Though some of the indicators are showing overbought level but still it’s worth buying. Moreover, the stock is forming a strong support at 15.02 levels. My target for this stock is 25-27 is coming days.

20-march-nektar

Think we missed something? Let us know what do you think about my 20-24 March Weekly Stock Market Outlook in the comments section below. 

(37)

Share via Twitter Share via Facebook Share via LinkedIn Share via Google Plus